Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Plain-language summary

This study investigates whether combining the drugs Imatinib and Artesunate improves treatment outcomes in patients with chronic myeloid leukemia. It included patients aged 18-85 who were newly diagnosed in the chronic phase or who had a suboptimal response to Imatinib therapy. The study is in Phase 2 and is active but not currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Active, not recruiting

Sponsor

Obafemi Awolowo University

Intervention

Imatinib, Artesunate

Start date

7/1/2025

Estimated completion

12/1/2026

Countries

Nigeria

Related genes

Locations

• Ile-Ife, Nigeria

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Newly diagnosed chronic phase CML patients
* Patients with sub-optimal response to imatinib therapy
* Ages between 18 years and 85 years with written informed consent

Exclusion Criteria:

* Patients with documented hypersensitivity to artesunate
* Patients with cardiovascular disease, pregnancy and inability to give consent will be excluded.
* Patients currently on any medication(s) that may interact with imatinib or affect its pharmacokinetics parameters (like rifampicin and ketoconazole) will be excluded.